David Jin - Fortress Biotech CFO Development
| FBIO Stock | USD 1.80 0.02 1.12% |
CFO
David Jin is CFO Development of Fortress Biotech
| Age | 33 |
| Address | 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 |
| Phone | 781 652 4500 |
| Web | https://www.fortressbiotech.com |
David Jin Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Jin against Fortress Biotech stock is an integral part of due diligence when investing in Fortress Biotech. David Jin insider activity provides valuable insight into whether Fortress Biotech is net buyers or sellers over its current business cycle. Note, Fortress Biotech insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fortress Biotech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Jin over a month ago Acquisition by David Jin of 5000 shares of Fortress Biotech at 0.56 subject to Rule 16b-3 | ||
David Jin over a month ago Disposition of tradable shares by David Jin of Fortress Biotech subject to Rule 16b-3 | ||
David Jin over two months ago Acquisition by David Jin of 2352 shares of Fortress Biotech at 1.7 subject to Rule 16b-3 |
Fortress Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3413) % which means that it has lost $0.3413 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.3964) %, meaning that it created substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 9th of June 2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -1.77. At this time, Fortress Biotech's Asset Turnover is very stable compared to the past year.Similar Executives
| Found 2 records | CFO Age | ||
| PMP CPA | Elevation Oncology | N/A | |
| Gurinder MBA | Ocean Biomedical | 58 | |
Management Performance
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.34 |
Fortress Biotech Leadership Team
Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO | ||
| Samuel Berry, General Secretary | ||
| Robyn Hunter, Ex Officer | ||
| Michael Esq, Executive Director | ||
| Thomas Schaible, Project Disease | ||
| George Avgerinos, Sr. VP of Biologics Operations | ||
| David Jin, CFO Development |
Fortress Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (2.81) % | ||||
| Current Valuation | 13.78 M | ||||
| Shares Outstanding | 19.92 M | ||||
| Shares Owned By Insiders | 25.41 % | ||||
| Shares Owned By Institutions | 15.25 % | ||||
| Number Of Shares Shorted | 1.67 M | ||||
| Price To Earning | (2.92) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Fortress Stock
When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 7.954 | Quarterly Revenue Growth 0.048 | Return On Assets (0.34) | Return On Equity (17.40) |
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.